DailyDoctor Archive Specialties Get app
All neurology briefings

The edition · Neurology

A statin after 70 cuts major vascular events but not dementia, and late-onset epilepsy tracks vascular risk

STAREE gives a large placebo-controlled answer on statins for primary prevention in older adults; a pooled analysis of six cohorts ties seizures starting after 65 to smoking, diabetes, kidney disease and stroke; and lecanemab moves plasma biomarkers in more than one direction.

The edition in brief

STAREE randomised 9,971 Australians aged 70 or over without cardiovascular disease, diabetes or dementia to atorvastatin 40 mg or placebo. Over a median 5.9 years, major cardiovascular events, including stroke, fell by 30% (HR 0.70, 0.61–0.82), but the co-primary composite of death, dementia or persistent disability did not change (HR 0.94, 0.84–1.05). In a pooled analysis of six US cohorts (42,257 people), late-onset epilepsy developed in 3.5% over about nine years and was associated with prior stroke (HR 1.99), diabetes (1.42), current smoking (1.39), chronic kidney disease (1.29), hypertension (1.17) and APOE ε4. A cohort of 197 patients on lecanemab found 34 of 130 plasma proteins changed: p-tau217 and GFAP moved towards normal, while TREM2 and synaptic markers moved further away. A meta-analysis of 36 trials found robot-assisted training improved arm motor function and daily activities after stroke, but not balance, with no clear dose–response. The pearl covers the work-up of a first seizure in an older adult.

In this edition

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this one is waiting in it.

QR code to install Daily Doctor
Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.

Tomorrow morning, before your first patient

One edition a day for neurology, written by the desk, every claim tied to its paper. Six minutes.

Get the app — free